Open AccessCandidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study
Author(s) -
Steven Kiddle,
Martina Sattlecker,
Petroula Proitsi,
Andrew Simmons,
Eric Westman,
Chantal Bazenet,
Sally K. Nelson,
Steven Williams,
Angela Hodges,
Caroline Johnston,
Hilkka Soininen,
Iwona Kłoszewska,
Patrizia Mecocci,
Magda Tsolaki,
Bruno Vellas,
Stephen J. Newhouse,
Simon Lovestone,
Richard Dobson
Publication year - 2013
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-130380
Subject(s) - biomarker , proteomics , dementia , proteome , disease , biomarker discovery , alzheimer's disease , replicate , bioinformatics , medicine , phenotype , biology , oncology , computational biology , genetics , gene , statistics , mathematics
A blood-based protein biomarker, or set of protein biomarkers, that could predict onset and progression of Alzheimer's disease (AD) would have great utility; potentially clinically, but also for clinical trials and especially in the selection of subjects for preventative trials. We reviewed a comprehensive list of 21 published discovery or panel-based (> 100 proteins) blood proteomics studies of AD, which had identified a total of 163 candidate biomarkers. Few putative blood-based protein biomarkers replicate in independent studies but we found that some proteins do appear in multiple studies; for example, four candidate biomarkers are found to associate with AD-related phenotypes in five independent research cohorts in these 21 studies: α-1-antitrypsin, α-2-macroglobulin, apolipoprotein E, and complement C3. Using SomaLogic's SOMAscan proteomics technology, we were able to conduct a large-scale replication study for 94 of the 163 candidate biomarkers from these 21 published studies in plasma samples from 677 subjects from the AddNeuroMed (ANM) and the Alzheimer's Research UK/Maudsley BRC Dementia Case Registry at King's Health Partners (ARUK/DCR) research cohorts. Nine of the 94 previously reported candidates were found to associate with AD-related phenotypes (False Discovery Rate (FDR) q-value < 0.1). These proteins show sufficient replication to be considered for further investigation as a biomarker set. Overall, we show that there are some signs of a replicable signal in the range of proteins identified in previous studies and we are able to further replicate some of these. This suggests that AD pathology does affect the blood proteome with some consistency.